MOLN Stock Overview
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF4.00 |
| 52 Week High | CHF7.14 |
| 52 Week Low | CHF3.87 |
| Beta | 0.64 |
| 1 Month Change | -21.72% |
| 3 Month Change | -29.58% |
| 1 Year Change | -33.77% |
| 3 Year Change | -74.13% |
| 5 Year Change | -81.82% |
| Change since IPO | -82.14% |
Recent News & Updates
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08
Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23Recent updates
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17
Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term
Nov 21Molecular Partners AG (VTX:MOLN) Analysts Are Way More Bearish Than They Used To Be
Jul 12Bearish: Analysts Just Cut Their Molecular Partners AG (VTX:MOLN) Revenue and EPS estimates
Jun 27Shareholder Returns
| MOLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 2.6% | -0.3% | -1.5% |
| 1Y | -33.8% | -40.6% | 7.5% |
Return vs Industry: MOLN exceeded the Swiss Biotechs industry which returned -41.6% over the past year.
Return vs Market: MOLN underperformed the Swiss Market which returned 6.8% over the past year.
Price Volatility
| MOLN volatility | |
|---|---|
| MOLN Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.2% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MOLN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MOLN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 169 | Patrick Amstutz | https://www.molecularpartners.com |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins.
Molecular Partners AG Fundamentals Summary
| MOLN fundamental statistics | |
|---|---|
| Market Cap | CHF131.35m |
| Earnings (TTM) | -CHF61.52m |
| Revenue (TTM) | CHF8.53m |
15.4x
P/S Ratio-2.1x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLN income statement (TTM) | |
|---|---|
| Revenue | CHF8.53m |
| Cost of Revenue | CHF48.03m |
| Gross Profit | -CHF39.51m |
| Other Expenses | CHF22.01m |
| Earnings | -CHF61.52m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | -463.44% |
| Net Profit Margin | -721.61% |
| Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparison